The Hyper-CVAD Regimen is an Optimal Pediatric-inspired Regimen for Adolescents and Adults With Acute Lymphoblastic Leukemia

Elias Jabbour; Hagop Kantarjian

doi:10.1016/j.clml.2020.09.001

The Hyper-CVAD Regimen is an Optimal Pediatric-inspired Regimen for Adolescents and Adults With Acute Lymphoblastic Leukemia

Elias Jabbour, Hagop Kantarjian

Leukemia

Research output: Contribution to journal › Editorial › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	63-65
Number of pages	3
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	21
Issue number	1
DOIs	https://doi.org/10.1016/j.clml.2020.09.001
State	Published - Jan 2021

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.clml.2020.09.001

Cite this

@article{8b4a296da2fd4c89a906026db71431d5,

title = "The Hyper-CVAD Regimen is an Optimal Pediatric-inspired Regimen for Adolescents and Adults With Acute Lymphoblastic Leukemia",

author = "Elias Jabbour and Hagop Kantarjian",

note = "Funding Information: E. Jabbour and H. Kantarjian report research grants from Abbvie, Amgen, Adaptive Biotechnologies, BMS, Pfizer, Genentech, and Takeda. Funding Information: E. Jabbour and H. Kantarjian report research grants from Abbvie , Amgen , Adaptive Biotechnologies , BMS , Pfizer , Genentech , and Takeda .",

year = "2021",

month = jan,

doi = "10.1016/j.clml.2020.09.001",

language = "English (US)",

volume = "21",

pages = "63--65",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "1",

}

TY - JOUR

T1 - The Hyper-CVAD Regimen is an Optimal Pediatric-inspired Regimen for Adolescents and Adults With Acute Lymphoblastic Leukemia

AU - Jabbour, Elias

AU - Kantarjian, Hagop

N1 - Funding Information: E. Jabbour and H. Kantarjian report research grants from Abbvie, Amgen, Adaptive Biotechnologies, BMS, Pfizer, Genentech, and Takeda. Funding Information: E. Jabbour and H. Kantarjian report research grants from Abbvie , Amgen , Adaptive Biotechnologies , BMS , Pfizer , Genentech , and Takeda .

PY - 2021/1

Y1 - 2021/1

UR - http://www.scopus.com/inward/record.url?scp=85096177029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096177029&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2020.09.001

DO - 10.1016/j.clml.2020.09.001

M3 - Editorial

C2 - 33191168

AN - SCOPUS:85096177029

SN - 2152-2650

VL - 21

SP - 63

EP - 65

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 1

ER -

The Hyper-CVAD Regimen is an Optimal Pediatric-inspired Regimen for Adolescents and Adults With Acute Lymphoblastic Leukemia

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this